Counteracting suppression of CFTR and voltage-gated K+ channels by a bacterial pathogenic factor with the natural product tannic acid

  1. Yajamana Ramu
  2. Yanping Xu
  3. Hyeon-Gyu Shin
  4. Zhe Lu  Is a corresponding author
  1. Howard Hughes Medical Institute, University of Pennsylvania, United States

Abstract

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) cause recurring bacterial infection in CF patients' lungs. However, the severity of CF lung disease correlates poorly with genotype. Antibiotic treatment helps dramatically prolong patients' life. The lung disease generally determines prognosis and causes most morbidity and mortality; early control of infections is thus critical. Staphylococcus aureus is a main cause of early infection in CF lungs. It secretes sphingomyelinase (SMase) C that can suppress CFTR activity. SMase C also inhibits voltage-gated K+ channels in lymphocytes; inhibition of these channels causes immunosuppression. SMase C's pathogenicity is further illustrated by the demonstration that once Bacillus anthracis is engineered to express high levels of SMase C, the resulting mutant can evade the host immunity elicited by a live vaccine because additional pathogenic mechanisms are created. By screening a chemical library, we find that the natural product tannic acid is an SMase C antidote.

https://doi.org/10.7554/eLife.03683.001

eLife digest

Cystic fibrosis is an inherited disease that mainly affects the lungs and the intestine. It is caused by defective copies of a protein called CFTR, which normally allows chloride ions to flow in and out of cells through the cell membrane. The activity of the CFTR protein is important for transferring fluid in and out of cells, and the dysfunctional CTFR protein causes the cells lining the lungs and the intestine to produce thick mucus. This leads to problems with breathing and absorbing nutrients, and makes the lungs of people with cystic fibrosis more susceptible to infections.

Recurring lung infections aggravate the symptoms of cystic fibrosis and worsen the predicted outcome for sufferers. A common skin bacterium, called Staphylococcus aureus, is one of the first to colonize the lungs of young cystic fibrosis patients. This pathogen releases an enzyme that can further reduce any residual activity of the defective CTFR protein. The enzyme—called sphingomyelinase C (or SMase C for short)—also interferes with the function of another protein that allows potassium ions to flow out of immune cells. This effect in turn reduces the body's ability to fight the infection.

Now Ramu et al. have found, by using cells grown in a laboratory, that the enzyme released by the bacteria would remain active long after the bacteria had been killed. This finding suggests that a combination therapy of antibiotics that kill the bacteria and a drug that inhibits the enzyme function may greatly improve treatments for cystic fibrosis.

Ramu et al. then tested a collection of over 2000 edible naturally-occurring chemicals and drugs, which are already approved for use in humans, to see if any could counteract the activity of the enzyme. A single natural chemical called tannic acid was shown to prevent both the negative effects on CTFR and those on the potassium channel protein.

Other pathogenic bacteria also produce an SMase C enzyme and Ramu et al. showed that tannic acid can also interfere with the anthrax bacterium's enzyme. This suggests that treatment with tannic acid may improve the outcome in a number of bacterial infections. Further experimental work is now needed to establish whether tannic acid can alleviate the symptoms of infectious disease in animal models.

https://doi.org/10.7554/eLife.03683.002

Introduction

The cystic fibrosis transmembrane conductance regulator (CFTR) Cl channel is activated when its regulatory (R) domain is phosphorylated by cyclic AMP-dependent protein kinase A (PKA) (Tabcharani et al., 1991). Mutations of CFTR cause CF disease that involves multiple organs (Knowles et al., 1983; Kerem et al., 1989; Riordan et al., 1989; Rommens et al., 1989). In the lungs of CF patients, defective CFTR leads to production of thick mucus that obstructs airways and thus predisposes the patients to recurring bacterial infection. Although CF disease originates from genetically defective CFTR protein, the severity of CF lung disease is not well correlated with genotype. The CF lung pathology is not fundamentally different from those of many other types of chronic pulmonary infectious and inflammatory diseases. Aggressive antibiotic treatment and supportive measures have prolonged the median life span of patients from 5 to 37 years (The Cystic Fibrosis Foundation, 2004). These observations underscore the profound impact of infections on progression and severity of CF lung disease. Given that the lung disease generally determines CF patients' prognosis and causes ∼90% of their morbidity and mortality, it is extremely important to effectively control or mitigate lung infections in the early stages of CF disease.

Staphylococcus aureus is a main cause of early infection in the lungs of CF patients (The Cystic Fibrosis Foundation, 2008). Most S. aureus strains, including methicillin-resistant S. aureus (MRSA), secrete the pathogenic factor sphingomyelinase (SMase) C, which cleaves sphingomyelin into phosphocholine and ceramide (Doery et al., 1963) (upper panel, Figure 1A). Our group has previously discovered that SMase C hydrolysis of sphingomyelin surrounding CFTR protein profoundly suppresses CFTR activity (Ramu et al., 2007). Thus, bacteria can further diminish critical residual CFTR activity in CF patients, worsening the negative impact of mutations. By inhibiting CFTR, SMase C-producing bacteria can also create a temporary condition, analogous to CFTR deficiency, in non-CF patients with lung infection. Additionally, compounding this already very serious problem, SMase C strongly inhibits the activity of Kv1.3 voltage-gated K+ (Kv) channels of lymphocytes (Xu et al., 2008). Inhibition of these channels is well known to cause immunosuppression (Chandy et al., 2004).

SMase C suppression of heretologously expressed and native CFTR currents.

(A) Sphingomyelin hydrolysis reactions catalyzed by SMases C and D. (B) and (C) Currents of an oocyte injected with cRNA encoding CFTR before or after activation with 50 µM forskolin and 1 mM IBMX in the bath solution (B) and activated CFTR currents pre- or post-application of SMase C from S.aureus (SaSMase C: 0.4 ng/μl) (C), elicited by stepping membrane voltage from the −30 mV holding potential to −80 mV and then to 50 mV. (D) Time course of normalized CFTR currents at 50 mV where the arrows indicate addition of forskolin plus IBMX (arrow 1) or SaSMase C (arrow 2) (mean ± s.e.m, n = 6). (E) Normalized current amplitude before or after activation by forskolin plus IBMX and post-SMase C treatment (mean ± s.e.m, n = 6). (F) and (G) Native currents of a Calu-3 cell before or after activation with 50 µM forskolin and 1 mM IBMX in the bath solution (F) and activated CFTR currents before and after addition of SaSMase C (G), elicited by stepping membrane voltage from the 0 mV holding potential to −80 mV and then to 80 mV. (H) Time course of normalized CFTR currents at 80 mV where the arrows indicate addition of forskolin plus IBMX (arrow 1) or SaSMase C (0.5 ng/μl; arrow 2) (mean ± s.e.m, n = 7). (I) Normalized current amplitude before or after activation by forskolin plus IBMX and post-SMase C treatment (mean ± s.e.m, n = 7).

https://doi.org/10.7554/eLife.03683.003

SMase C's pathogenicity is further illustrated by the disturbing characteristics reported for a genetically engineered Bacillus anthracis mutant. Natural B. anthracis, against which the live STI-1 (Sanitary Technical Institute, USSR) vaccine provides effective protection, produces little SMase C due to a ‘defective’ regulatory gene. However, once B. anthracis is engineered to express high levels of SMase C, the resulting mutant not only remains lethal but also evades the host immunity elicited by the live vaccine because additional pathogenic mechanisms are generated (Pomerantsev et al., 1997). Thus, it is important to find effective means to counteract the SMase C action.

Results and discussion

Experimentally, the CFTR channels are often activated by boosting the concentration of intracellular cAMP with a combination of the adenylate cyclase activator forskolin and the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) (Csanady et al., 2000). Figure 1B shows current of CFTR heterologously expressed in a Xenopus oocyte bathed in a forskolin- and IBMX-containing solution. Following exposure to extracellular SMase C from S. aureus, the CFTR current was markedly diminished in a time-dependent manner (Figure 1C–E). To investigate whether SMase C also suppresses native CFTR current, we tested the enzyme's effect on CFTR current in Calu-3 cells (a lung epithelial cell line commonly used in CFTR research) after activating their CFTR channels with forskolin and IBMX (Figure 1F–H). As in oocytes, SMase C suppressed CFTR current in Calu-3 cells (Figure 1G–I), a result confirming that this SMase C effect on CFTR activity is not unique to the oocyte heterologous expression system.

Individual strains of a given bacterium species may be expected to secrete different isoforms of SMase C. We compared three isoforms from S. aureus to learn their behaviors (Figure 2A; only isoform #1 was used elsewhere). All three recombinant isoforms suppressed CFTR current albeit with differing specific activity (Figure 2B). Two isoforms lost activity over 96 hr, and one retained full activity; all three isoforms exhibited measurable activity for at least 48 hr. It follows that secreted SMase C can remain active for a considerable time following death of the bacteria. Thus, while antibiotics remain critical in combating the infection, an effective means to counteract SMase C action would be important in limiting the negative impact of the bacterial infection on the host.

Effects of isoforms and mutations on SaSMase C suppression of CFTR current.

(A) N-terminal sequences of three SaSMase C isoforms. (B) Percentage of SaSMase C suppression of CFTR current by individual isoforms at 1, 48 and 96 hr after final purification of SMase C (mean ± s.e.m, n = 5), where the final concentration was 0.4 ng/µl for isoform 1 and 40 ng/µl for isoforms 2 and 3. (C) Percentage of SaSMase C suppression of wild-type and mutant CFTR currents activated by expressing cRNA encoding the PKA catalytic subunit (mean ± s.e.m, n = 7–10).

https://doi.org/10.7554/eLife.03683.004

We previously found that at levels beyond that required to achieve maximal CFTR activation, PKA's catalytic subunit significantly lessens suppression of CFTR current by SMase C (Ramu et al., 2007). This observation suggests that SMase C modifying the head group chemistry of sphingomyelin molecules surrounding CFTR makes activation of CFTR more energetically difficult, and this SMase C action can be markedly overcome by ‘over-phosphorylating’ the channel's R-domain until all four sites are phosphorylated. This hypothesis implies that mutant CFTR channels with individual key phosphorylation sites ablated would suffer more pronounced suppression by SMase C at these ‘supersaturating’ levels of PKA's catalytic subunit. To test this prediction, we replaced each of the four phosphorylation sites, one at a time, with alanine and examined SMase C's effect on these single-mutant channels. As a control, we showed that in the presence of a supersaturating level of PKA's catalytic subunit, SMase C suppressed only 25% of the wild-type CFTR current (Figure 2C). In contrast and as predicted, under the same experimental condition, SMase C suppressed 40–65% of the mutants' currents. A second corollary of our hypothesis is that a β adrenergic receptor agonist should alleviate the SMase C-caused suppression of CFTR current by boosting intracellular cAMP. In fact, β receptor agonists are routinely used as bronchodilators in patients suffering from pulmonary infectious and inflammatory diseases. Thus, application of β receptor agonists would not be contraindicated in cases of infection by SMase C-positive bacteria and likely be beneficial. However, given that a β receptor agonist unlikely causes overphosphorylation of the R domain, it may only modestly counteract the SMase C-dependent suppression of CFTR current.

To develop a clinically suitable drug from scratch is difficult and costly. One shortcut is to find novel medical benefits in already approved drugs or edible natural products. As such, we screened a chemical library (Spectrum 2000) consisting of approved drugs and natural products, each at 10 µM concentration. We employed a fluorescence-based assay (Amplex Red) involving a series of coupled enzymatic reactions. Figure 3A is a correlation plot of the Z scores obtained from two repeated screens. A positive result suggests an antagonizing effect of the tested compound on SMase C or on one or more of the coupled reactions. The 27 compounds with higher Z scores were then examined electrophysiologically for their antagonistic effects on SMase C (Figure 3B). We found that, of those 27 compounds at 10 µM, only tannic acid exhibited a clear SMase C-antagonizing effect (Figure 3B,C). Tannic acid was just as effective at concentrations down to 200 nM (Figure 3D). Furthermore, we found that it also antagonized SMase C of B. anthracis (Figure 4A–C).

Tannic acid (TA) counteracts SaSMase C and SMase D suppression of CFTR current.

(A) Correlation plot of Z scores (raw scores minus the mean of the population, divided by the standard deviations of individual compounds) of individual compounds tested in two repeated screens; 27 compounds with higher Z scores are colored orange. (B) Percentage SaSMase C suppression of CFTR currents in the presence of 27 tested compounds, each at 10 µM. (C) Time course of normalized CFTR currents at 50 mV without or with 10 µM tannic acid (TA) present in the bath; arrow indicates addition of SaSMase C (0.6 ng/µl). (D) and (E) Time courses of normalized CFTR currents at 50 mV without and with 100 or 200 nM (D) or 300 nM (E) tannic acid present in the bath; arrow indicates addition of SaSMase C (D) and SMase D (E) (mean ± s.e.m, n = 3–5). (F) Apparent activities of SaSMase C (1 and 2) or SMase D (0.6 ng/μl) (3) plotted against the concentration of tannic acid, where the activities are expressed as half-time of the time course of sphingomyelin hydrolysis (1) or CFTR inhibition (2 and 3), which were obtained by the Amplex red assay (1) or by electrophysiological recordings (2 and 3). The half-time values were normalized to the corresponding ones obtained in the presence of relevant enzymes and the absence of tannic acid.

https://doi.org/10.7554/eLife.03683.005
Tannic acid antagonizes suppression of CFTR and Kv1.3 currents by SMase C of B.anthracis (BaSMase C).

(A) and (B) Currents of an oocyte injected with cRNA encoding CFTR, which was activated as in Figure 1, before (pre) and after (post) addition of BaSMase C (0.6 ng/μl) without (A) and with (B) 200 nM TA present. (C) Time course of normalized CFTR currents at 50 mV without or with 200 nM TA present in the bath; arrow indicates addition of BaSMase C (mean ± s.e.m, n = 10). (D) and (E) Currents of an oocyte injected with cRNA encoding Kv1.3 before (pre) and after (post) addition of BaSMase C without (D) and with (E) 200 nM TA, elicited by stepping membrane voltage from the −80 mV holding potential to 20 mV and then back to −80 mV. (F) Time course of normalized Kv1.3 currents at 20 mV without or with 200 nM TA in the bath; arrow indicates addition of BaSMase C (mean ± s.e.m, n = 4).

https://doi.org/10.7554/eLife.03683.006

Tannic acid is known to interact with many other proteins with apparent Kd or EC50 between 8 µM and 150 mM (Gabbott, 2008). Consequently, high concentrations of tannic acid (5–50 mM) are often used to fix cells in EM studies (Hayat, 1981; Afzelius, 1992; Bozzola and Russell, 1992). To our knowledge, a EC50 range of 50–100 nM observed in our study is by far the lowest concentration range at which tannic acid is found to bind effectively to a protein and/or to produce a meaningful biological effect (Figure 3F). Although tannic acid has been reported to bind to the choline group of phosphatidylcholine (PC), it does not appear to antagonize SMase C activity by binding to PC and thereby preventing SMase C from accessing sphingomyelin because tannic acid binds to PC only at much higher concentrations than what is required to antagonize SMase C activity (Kalina and Pease, 1977; Simon et al., 1994). Furthermore, the EC50 (∼50 nM) of tannic acid for antagonizing the SMase C-catalyzed sphingomyelin hydrolysis in a biochemical reaction (involving no PC) is comparable to its EC50 (∼100 nM) for antagonizing SMase C suppression of CFTR activity in a biological membrane (Figure 3F).

To assess the relative specificity of tannic acid's antagonizing effect on SMase C, we tested tannic acid against bacterial SMase D. Like SMase C, SMase D specifically hydrolyzes sphingomyelin (bottom panel, Figure 1A). However, unlike SMase C, SMase D removes only the choline group rather than the entire phosphocholine head group from sphingomyelin, leaving ceramide-1-phosphate instead of ceramide behind in the membrane. Our group previously showed that SMase D also suppresses CFTR activity (Ramu et al., 2007). Here, we show that tannic acid at 300 nM slightly slowed down SMase D suppression of CFTR activity (Figure 3E). In contrast, as shown above, tannic acid at 200 nM essentially eliminated SMase C suppression of CFTR activity (Figure 3D). Thus, tannic acid antagonizes SMase C and SMase D with differing potency (Figure 3F).

In lymphocytes, Kv1.3 channels help maintain a sufficiently negative resting membrane potential to sustain an adequate driving force for Ca2+ entry which acts as a key signal to activate lymphocytes (DeCoursey et al., 1984; Matteson and Deutsch, 1984; Cahalan and Chandy, 2009). Consequently, inhibition of Kv1.3 channels causes immunosuppression, a finding that has stimulated the development of inhibitors of Kv1.3 as effective immunosuppressants to treat autoimmune diseases (Chandy et al., 2004). On this backdrop, we previously showed that SMase C, by removing the phosphoryl head group of sphingomyelin molecules around Kv1.3 channels, profoundly diminishes these channels' activity (Xu et al., 2008). The underlying mechanism is that removal of the negatively charged phosphoryl group makes it energetically more difficult for positively charged voltage sensors to transition to the activated state. Here, we find that tannic acid can also effectively counteract suppression of Kv1.3 activity by SMase C (Figure 4D–F).

As illustrated above, we have shown that tannic acid is an antidote to SMase C. It is a readily available and inexpensive natural product, widely and abundantly used in the food industry. The US Food and Drug Administration terms it Generally Recognized As Safe (GRAS) (FDA, 2013). The use of tannic acid to treat various diseases was reported as early as 1850 (Alison, 1850; Allegrini and Costantini, 2012), for example in the treatment of human diarrhea. Recently reported clinical doses are 0.5–1 g (Bian et al., 2009), giving an estimated concentration in human body fluids of 8–16 µM, or 40–80 times higher than required to antagonize SMase C action. We suggest that tannic acid be considered in attempts to protect against B. anthracis mutants engineered to over-express SMase C, in the unfortunate event of an outbreak, or to lessen the harm caused by natural SMase C-positive bacteria including MRSA, in both CF and non-CF patients.

Materials and methods

Molecular biology and electrophysiological recordings

Request a detailed protocol

The CFTR and PKA-C cDNAs were subcloned in the pGEMHE plasmid (Liman et al., 1992). Mutant CFTR cDNAs were obtained through PCR-based mutagenesis and confirmed by DNA sequencing. The cRNAs were synthesized with T3 or T7 polymerase using the corresponding linearized cDNAs as templates. Channel currents were recorded from whole oocytes previously injected with the corresponding cRNAs and stored at 18°C, using a two-electrode voltage clamp amplifier (OC-725C; Warner, Hamden, CT), filtered at 5 kHz and sampled at 50 kHz using a Digidata 1322 interfaced to a PC. The resistance of electrodes filled with 3 M KCl was 0.2–0.3 MΩ. Molecular Devices pClamp 8 software was used for amplifier control and data acquisition. Unless specified otherwise, the bath solution contained (in mM): 95 NaCl, 5 KCl, 0.3 CaCl2, 1 MgCl2 and 10 HEPES; pH was adjusted to 7.6 with NaOH. CFTR current from the Calu-3 cell line was recorded in the whole cell configuration with a patch-clamp amplifier (200B; Axopatch), filtered at 5 kHz and sampled at 50 kHz using a Digidata 1322 interfaced to a PC. Electrodes were fire polished (2–4 MΩ) and coated with beeswax. Capacitance and series resistance were electronically compensated. Molecular Devices pClamp 8 software was used for amplifier control and data acquisition. The bath solution contained (in mM) 145 NaCl, 5 KCl, 0.3 CaCl2, 1 MgCl2, 10 HEPES (pH 7.30 adjusted with NaOH) and the electrode solution contained (in mM) 140 KCl, 10 EGTA, 1 CaCl2, 1 MgCl2, 10 HEPES (pH 7.30 adjusted with KOH). SMases were manually added to the recording chamber to test their effects.

Production of recombinant SMases

Request a detailed protocol

The cDNAs of SMase C were produced with PCR, primed with a pair of oligonucleotides corresponding to the 5ʹ or 3ʹ translated regions against the genomic DNA isolated from B. anthracis and S. aureus (isoform 1, accession number AAB32218; isoform 2, BAB43091 and isoform 3, ZP_01242591), respectively. To produce recombinant SMases C and D, Escherichia coli BL21 (DE3) cells were transformed with the respective cDNAs cloned into pET30 vector (Novagen, San Diego, CA), grown in LB medium to ∼0.6 OD at 600 nm, and induced with 1 mM IPTG for 2 hr. The bacteria were harvested, resuspended, and sonicated. The resulting samples were loaded onto a cobalt affinity column and eluted by stepping the imidazole concentration from 50 to 500 mM (all SMase proteins contain N- and C-terminal His tags). The imidazole was later removed by dialysis.

Quantification of SMase C inhibition with an Amplex red fluorescence-based assay

Request a detailed protocol

We screened the Spectrum 2000 compound library with Amplex red assay which is based on the following coupled reactions. First, sphingomyelinase hydrolyzes sphingomyelin, yielding ceramide and phosphocholine. Second, an alkaline phosphatase hydrolyses phosphocholine, yielding choline. Third, choline is oxidized by choline oxidase to betaine and H2O2. Finally, H2O2, in the presence of horseradish peroxidase, reacts with Amplex Red reagent in a 1:1 stoichiometry to generate the highly fluorescent product, resorufin. Resorufin has absorption and fluorescence emission maxima of approximately 571 nm and 585 nm, respectively. During the screen, individual wells of a PerkinElmer OptiPlateTM-384 HB black plate containing Spectrum 2320 compounds (each at 10 μM) dissolved in DMSO were added with 20 μl of a mixture containing sphingomyelin (100 μM), alkaline phosphatase (16 U/ml), choline oxidase (0.4 U/ml), horseradish peroxidase (4 U/ml), Amplex red (100 μM), and triton X (0.4%) (Amplex red sphingomyelinase assay kit A12220; Invitrogen, Grand Island, NY), using a Bio Tek microdispenser (Janus Automated Workstation, PerkinElmer, Waltham, MA). To start the enzymatic reaction, 20 μl of a solution containing SaSMase (30 nM) was dispensed into individual wells. For chemical library screening, SMase C activity was quantified from the intensity ratio of fluorescence excited at 570 nm and detected at 590 nm in the presence and absence (DMSO only) of tested compounds whereas it was quantified by monitoring absorbance at 570 nm in the tannic acid dose–response study.

References

  1. Book
    1. Bozzola JJ
    2. Russell LD
    (1992)
    Electron microscopy: principles and techniques for biologists
    Jones and Bartlett.
    1. FDA
    (2013)
    Food and drugs
    21.
  2. Book
    1. Gabbott P
    (2008)
    Principles and applications of thermal analysis
    Blackwell Publication Limited.
  3. Book
    1. Hayat MA
    (1981)
    Fixation for electron microscopy
    London: Academic press.
    1. The Cystic Fibrosis Foundation
    (2004)
    Patient registry annual data report
    Bethesda, M.D.
    1. The Cystic Fibrosis Foundation
    (2008)
    Annual report
    Bethesda, M.D.

Article and author information

Author details

  1. Yajamana Ramu

    Department of Physiology, Perelman School of Medicine, Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, United States
    Contribution
    YR, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.
  2. Yanping Xu (deceased)

    Department of Physiology, Perelman School of Medicine, Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, United States
    Contribution
    YX, Conception and design, Acquisition of data, Analysis and interpretation of data
    Competing interests
    The authors declare that no competing interests exist.
  3. Hyeon-Gyu Shin

    Department of Physiology, Perelman School of Medicine, Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, United States
    Contribution
    H-GS, Acquisition of data, Analysis and interpretation of data
    Competing interests
    The authors declare that no competing interests exist.
  4. Zhe Lu

    Department of Physiology, Perelman School of Medicine, Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, United States
    Contribution
    ZL, Conception and design, Analysis and interpretation of data, Drafting or revising the article
    For correspondence
    zhelu@mail.med.upenn.edu
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institute of General Medical Sciences (GM55560)

  • Yajamana Ramu
  • Yanping Xu

Howard Hughes Medical Institute

  • Hyeon-Gyu Shin
  • Zhe Lu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We thank D Gadsby for CFTR cDNA in the pGEMHE vector, S Billington for SMase D cDNA, D Schultz and S Hodwadekar for advice and technical assistance, and P De Weer for critical review of the manuscript. Small molecule screening assay was performed in the Molecular Screening Facility of the Wistar Institute. Z Lu is an Investigator of the Howard Hughes Medical Institute.

Copyright

© 2014, Ramu et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,291
    views
  • 75
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yajamana Ramu
  2. Yanping Xu
  3. Hyeon-Gyu Shin
  4. Zhe Lu
(2014)
Counteracting suppression of CFTR and voltage-gated K+ channels by a bacterial pathogenic factor with the natural product tannic acid
eLife 3:e03683.
https://doi.org/10.7554/eLife.03683

Share this article

https://doi.org/10.7554/eLife.03683

Further reading

    1. Cell Biology
    2. Neuroscience
    Luis Sánchez-Guardado, Peyman Callejas Razavi ... Carlos Lois
    Research Article

    The assembly and maintenance of neural circuits is crucial for proper brain function. Although the assembly of brain circuits has been extensively studied, much less is understood about the mechanisms controlling their maintenance as animals mature. In the olfactory system, the axons of olfactory sensory neurons (OSNs) expressing the same odor receptor converge into discrete synaptic structures of the olfactory bulb (OB) called glomeruli, forming a stereotypic odor map. The OB projection neurons, called mitral and tufted cells (M/Ts), have a single dendrite that branches into a single glomerulus, where they make synapses with OSNs. We used a genetic method to progressively eliminate the vast majority of M/T cells in early postnatal mice, and observed that the assembly of the OB bulb circuits proceeded normally. However, as the animals became adults the apical dendrite of remaining M/Ts grew multiple branches that innervated several glomeruli, and OSNs expressing single odor receptors projected their axons into multiple glomeruli, disrupting the olfactory sensory map. Moreover, ablating the M/Ts in adult animals also resulted in similar structural changes in the projections of remaining M/Ts and axons from OSNs. Interestingly, the ability of these mice to detect odors was relatively preserved despite only having 1–5% of projection neurons transmitting odorant information to the brain, and having highly disrupted circuits in the OB. These results indicate that a reduced number of projection neurons does not affect the normal assembly of the olfactory circuit, but induces structural instability of the olfactory circuitry of adult animals.

    1. Cell Biology
    2. Physics of Living Systems
    Pyae Hein Htet, Edward Avezov, Eric Lauga
    Research Article

    The endoplasmic reticulum (ER), the largest cellular compartment, harbours the machinery for the biogenesis of secretory proteins and lipids, calcium storage/mobilisation, and detoxification. It is shaped as layered membranous sheets interconnected with a network of tubules extending throughout the cell. Understanding the influence of the ER morphology dynamics on molecular transport may offer clues to rationalising neuro-pathologies caused by ER morphogen mutations. It remains unclear, however, how the ER facilitates its intra-luminal mobility and homogenises its content. It has been recently proposed that intra-luminal transport may be enabled by active contractions of ER tubules. To surmount the barriers to empirical studies of the minuscule spatial and temporal scales relevant to ER nanofluidics, here we exploit the principles of viscous fluid dynamics to generate a theoretical physical model emulating in silico the content motion in actively contracting nanoscopic tubular networks. The computational model reveals the luminal particle speeds, and their impact in facilitating active transport, of the active contractile behaviour of the different ER components along various time–space parameters. The results of the model indicate that reproducing transport with velocities similar to those reported experimentally in single-particle tracking would require unrealistically high values of tubule contraction site length and rate. Considering further nanofluidic scenarios, we show that width contractions of the ER’s flat domains (perinuclear sheets) generate local flows with only a short-range effect on luminal transport. Only contractions of peripheral sheets can reproduce experimental measurements, provided they are able to contract fast enough.